Literature DB >> 33438994

Liquid CO2 Formulated Mesoporous Silica Nanoparticles for pH-Responsive Oral Delivery of Meropenem.

Aun Raza1,2, Fekade Bruck Sime1,2, Peter J Cabot1, Jason A Roberts1,2,3,4, James R Falconer1, Tushar Kumeria1,5, Amirali Popat1,6.   

Abstract

Meropenem (MER) is an effective broad-spectrum antibiotic currently only available in the parenteral form requiring frequent drug preparation and administration due to its extremely poor stability. The unavailability of oral Meropenem is primarily due to its ultrapoor handling and processing stability, hydrophilic nature that inhibits the passive diffusion across the gastrointestinal (GI) epithelium, degradation in the harsh gastric environment, and GI expulsion through enterocyte efflux glycoproteins. In this regard, we have developed an oral drug delivery system that confines MER into mesoporous silica nanoparticles (MSNs i.e, MCM-41 ∼141 nm) using a novel liquid carbon dioxide (CO2) method. MER was efficiently encapsulated within pristine, phosphonate (negatively charged MSN), and amine (positively charged MSN) modified MSNs with loading capacity ranging between 25 wt % and 31 wt %. Next, the MER-MCM-NH2 particles were electrostatically coated with Eudragit S100 enteric polymer that protected MER against gastric pH (pH 1.9) and enabled site-specific delivery in the small intestine (pH 6.8). Cellular uptake results in RAW 264.7 macrophage, Caco-2, and LS174T cells confirming the efficient cellular uptake of nanoparticles in all three cell lines. More importantly, the bidirectional transport (absorptive and secretory) of MER across Caco-2 monolayer was significantly improved for both MSN-based formulations, particularly MSNs coated with a polymer (Eud-MER-MCM-NH2) where permeability was significantly enhanced (∼2.4-fold) for absorptive transport and significantly reduced (∼1.8-fold) for secretory transport. Finally, in vitro antibacterial activity [minimum inhibitory concentration (MIC)] and time-kill assay against S. aureus and P. aeruginosa showed that drug-loaded nanoparticles were able to retain antibacterial activity comparable to that of free MER in a solution at equivalent dose. Thus, Eudragit-coated silica nanoparticles could offer a promising and novel solution for oral delivery of Meropenem and other such drugs.

Entities:  

Keywords:  Meropenem; liquid CO2; mesoporous silica nanoparticles; oral antibiotics; oral drug delivery

Mesh:

Substances:

Year:  2021        PMID: 33438994     DOI: 10.1021/acsbiomaterials.0c01284

Source DB:  PubMed          Journal:  ACS Biomater Sci Eng        ISSN: 2373-9878


  6 in total

1.  Formulation and Biological Evaluation of Mesoporous Silica Nanoparticles Loaded with Combinations of Sortase A Inhibitors and Antimicrobial Peptides.

Authors:  Sitah Alharthi; Zyta M Ziora; Taskeen Janjua; Amirali Popat; Peter M Moyle
Journal:  Pharmaceutics       Date:  2022-05-04       Impact factor: 6.525

2.  Superiority of Mesoporous Silica-Based Amorphous Formulations over Spray-Dried Solid Dispersions.

Authors:  Hongwei Zhang; Minglu Li; Jianmin Li; Anjali Agrawal; Ho-Wah Hui; Demin Liu
Journal:  Pharmaceutics       Date:  2022-02-16       Impact factor: 6.321

Review 3.  Application of nanotechnology in the diagnosis and treatment of acute pancreatitis.

Authors:  WeiLu Jia; LinFeng Xu; WenJing Xu; Meng Yang; YeWei Zhang
Journal:  Nanoscale Adv       Date:  2022-03-19

4.  A PEGylated Nanostructured Lipid Carrier for Enhanced Oral Delivery of Antibiotics.

Authors:  Seyed Ebrahim Alavi; Urooj Bakht; Maedeh Koohi Moftakhari Esfahani; Hossein Adelnia; Seyed Hossein Abdollahi; Hasan Ebrahimi Shahmabadi; Aun Raza
Journal:  Pharmaceutics       Date:  2022-08-11       Impact factor: 6.525

Review 5.  Biocompatible Supramolecular Mesoporous Silica Nanoparticles as the Next-Generation Drug Delivery System.

Authors:  Farahidah Mohamed; May K Oo; Bappaditya Chatterjee; Batoul Alallam
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

6.  Mesoporous Silica Nanoparticles Improve Oral Delivery of Antitubercular Bicyclic Nitroimidazoles.

Authors:  Chee Wei Ang; Lendl Tan; Zhi Qu; Nicholas P West; Matthew A Cooper; Amirali Popat; Mark A T Blaskovich
Journal:  ACS Biomater Sci Eng       Date:  2021-08-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.